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Background: Increasing development of tuberculosis (TB) resistance to the currently available drugs 
including second-line anti-TB drugs that are being used for treatment of Multi-Drug Resistant TB (MDR-TB) 
patients has frustrated efforts to control TB worldwide. Ethionamide (Eth) is one of the drugs used in the 
regimen for treatment of these patients.  
Objective: To determine level of Ethionamide resistance among second-line anti-tuberculosis drugs in 
Mycobacterium tuberculosis (MTB) strains isolated in Kenya. 
Design: A retrospective lab-based study involving archived strains from previous studies carried out at the 
Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) from 2002 to 
2007.  
Setting: Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI). 
Methods: A total of 216 MTB strains with pre-determined first-line drug susceptibility testing (DST) results 
were used including 78 first-line resistant to individual and combined drugs, and 138 susceptible to 
streptomycin, rifampicin, isoniazid and ethambutol. The strains were subjected to DST to ethionamide among 
other second-line.  
Results: Thirty two [32/216 (14.8%)] strains showed resistance to second-line drugs. Resistance to Eth was the 
highest [18/32 (56.3%)] including co-resistance with isoniazid [8/18 (44.4%)]. Nine [9/18 (50%)] strains were 
fully resistant and 9 [9/18 (50%)] were intermediate resistant to Eth.  
Conclusion: Unexplainable high levels of Eth resistance is a cause for concern. This will impact negatively on 
the outcome of management of MDR-TB especially in Kenya where the use of this drug is almost mandatory. 
Close monitoring of Eth before initiating individual patient management may be necessary.  
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Introduction 
Tuberculosis (TB) is far from being controlled. 
Despite the fact that several reasons could be 
attributed to this, a significant contributing factor 
maybe the development of resistance to the currently 
available drugs due to the successful adaptation of the 
pathogen to these drugs.  
Anti-TB drugs are a two-edged sword. While they 
destroy pathogenic Mycobacterium tuberculosis 
(MTB) they also select for drug resistant MTB against 
which those drugs are then ineffective1. Drug resistant 
TB is a state where MTB organisms are resistant to 
antimicrobials agents at the levels attainable in blood 
and tissue2. 
Infection with Multi-Drug Resistant tuberculosis 
(MDR-TB) complicates TB treatment by necessitating 
the selection of substitute drugs, collectively referred 
to as second-line drugs, to replace the ineffective first-
line drugs. Second-line anti-TB drugs are being used 
for treatment of MDR-TB patients. Ethionamide (Eth) 
one of the most frequently used and efficacious 
second-line drugs is used in treatment of MDR-TB 
with a combination of the following drugs; an 
injectable anti-TB aminoglycoside (e.g., amikacin, 
capreomycin, Kanamycin), a fluoroquinolone (e.g., 
gatifloxacin, ciprofloxacin, ofloxacin), ethambutol, 
pryrazinamide, isoniazid, rifampicin, cycloserine and 
para-amino salicylic acid. Eth is never and should 
never be used alone3. 
Eth is an efficacious, relatively non-toxic and cheap, 
and easily available drug, which has been in use since 
the 1960s. When used within the range of 0.5 to 5.0 
mg/ml in vitro it leads to a loss of acid fastness in 
MTB by inhibiting mycolic acid biosynthesis4. Eth is 
a structural analog of isoniazid5, 6. Both compounds 
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are known to inhibit mycolic acid biosynthesis7. Low-
level isoniazid-resistant strains frequently display 
low-level Eth resistance, while high-level isoniazid-
resistant strains typically remain Eth susceptible8. The 
structural similarity and existence of cross-resistant 
phenotypes suggested that these two drugs share a 
common molecular target9.  
In Kenya Eth is used in the treatment of MDR-TB 
patients according to World Health Organization 
(WHO) standards. Patients diagnosed with MDR-TB 
based on DST results receive a standardised second-
line regimen consisting of ofloxacin, cycloserine, Eth 
and amikacin. Ethambutol and pyrazinamide are also 
added to the regimen based on DST results10, 11. 
Treatment of MDR-TB takes months to years and 
must be done on the basis of susceptibility testing, it 
is impossible to treat such patients without this 
information. If treating a patient with suspected 
MDR-TB, the patient should be started on 
streptomycin, isoniazid, rifampicin, ethambutol, 
pyrazinamide, moxifloxacin and cycloserine pending 
the result of laboratory susceptibilty testing12. 
Materials and Methods 
Samples: A total of 216 MTB strains were used in 
this study. The strains were obtained from the 
archives of previous studies at the Centre for 
Respiratory Diseases Research (CRDR), Kenya 
Medical Research Institute (KEMRI). They included 
both first-line drug resistant and first-line susceptible 
strains. All the first-line resistant strains obtained 
during the period between 2002 and 2007 available 
were taken and randomly selected the first-line 
susceptible strains.  
Table 1: Type of first-line strains used in the study.  
First-line resistant strains (78)  First-line 
susceptible strains  
Isoniazid related resistant strains 
(73)  
Rifampicin related resistant 
strains (25)  
Streptomycin related resistant 
strains (24)  
Ethambutol related resistant 
strains (11)  
Multi-drug resistant strains (25)  
             138  
 
Laboratory procedures: The strains were first 
subcultured on fresh Lowenstein Jensen (LJ) media 
and incubated until there was growth to obtain fresh 
strains with confluent growth. Drug susceptibility 
testing (DST) was performed on LJ media using the 
resistant ratio (RR) method. The drug used was Eth 
among other second-line drugs13. 
Drug containing LJ media were made by adding 
appropriate amounts of drugs aseptically to LJ media 
before inspissation. First a stock solution were 
prepared and the drug solution sterilised using a 
membrane filter with a size of 0.45µm to maintain 
aseptic conditions. Appropriate working 
concentrations of each drug were made using sterile 
distilled water and then added aseptically to the LJ 
media. Five ml of the media was then dispensed into 
sterile 1 ounce universal bottles and then inspissated 
for 1 hour at a temperature of 85°C13.   
RR method was used for Eth. Dilutions of the drug 
was made and incorporated into the LJ media. The 
final drug concentrations that was used for Eth was 
10-160 µg/ml doubling dilutions13.  
Each bacterial suspension was prepared by adding 
approximately 4 mg moist weight of the test sample of 
the bacterial mass visualized as 2/3 loopful of a 3mm 
internal diameter, 24 standard wire gauge wire loop 
into 1 ml of sterile distilled water in a 7 ml bijou 
bottle containing three 3mm glass beads. This 
suspension was vortexed for 30 seconds to produce a 
uniform suspension of 1.0 McFarland turbidity 
standard (107 CFU/ml). A standardized inoculum of 
0.1 ml of the bacterial suspension was inoculated onto 
drug-free and drug containing LJ media using a 
loopful of a 3 mm diameter, 27 standard wire gauge 
wire loop13. These cultures were then incubated at a 
temperature of 37°C for four weeks with weekly 
observations for growth.  
Interpretation of results:  In the RR method growth 
of less than 20 colonies on the media containing the 
lowest concentration of the drug was taken as the end 
point. The results were recorded as RR, defined as the 
minimum inhibitory concentration (MIC) of the test 
organism divided by MIC of the H37Rv control 
strain. A RR of 2 or less showed susceptibility, a RR 
of between 3 and 5 showed intermediate resistance 
and a RR of 6 and above showed resistance. The 
results for RR were interpreted as either fully 
resistant, intermediate resistant or susceptible13. 
Quality control and safety: All manipulations were 
done in a class II biosafety under sterile conditions. 
Control strain MTB H37Rv which is susceptible to all 
the drugs was included in each new batch of media. 
Control strains of known resistance patterns for each 
drug tested were also included. LJ media was 
prepared using fresh eggs (less than seven days old) 
and sterility check was carried out on all batches of 
media by incubating a few slopes of the LJ media 
randomly at 37°C for at least five days and checked 
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daily to ensure that there was no contamination. All 
batches of media for DST were stored at 4°C for not 
longer than four weeks from date of preparation. 
Preparation of suspensions from each strain was done 
using individual sterile wire loops per inoculation to 
avoid cross-contamination between the strains14. 
Ethical considerations: This study was cleared by 
both the Kenya Medical Research Institute (KEMRI) 
Scientific Steering Committee (SSC) and the National 
Ethical Review Committee (ERC). 
Data analysis: Using S.P.S.S. computer data analysis 
programme, analysis of data was done using chi-
square to compare resistance and susceptibility among 
the drugs and to compare resistance and susceptibility 
between the first line susceptible and resistant 
strains15. The data was presented inform of tables. 
 
Results 
Of the 216 strains tested, 198 (91.7%) were sensitive 
and 18 (8.3%) were resistant to Eth. A total of 32 
[32/216 (14.8%)] strains showed resistance to second-
line drugs. Of these, nine (47.4%) were fully resistant 
and nine (69.2%) were intermediate resistant to Eth 
(Table 2 and 3). 
 













Eth 198 (91.67) 9 (4.17) 9 (4.17) 216 (100) 
   
Of the 32 resistant strains a total of 18 (56.3%) 
isolates were resistant to Eth. Eth showed the highest 
number of resistance with seven (41.2%) strains being 
fully resistant to Eth alone and two strains being 
resistant to Eth and two other second-line drugs 
(Table 3). 
Table 3: Specific resistant levels in Ethionamide 
Type of strain Numbers of strains 
(n) 
Mono-resistant to Eth  7 
Fully resistant to 
Gatifloxacin and Eth 
1 
 Fully resistant to Eth and 
Cycloserine 1 
Intermediate resistant to Eth 9 
Total Resistant 18 
 
Of the 25 rifampicin resistant strains tested, 23 (92%) 
were found to be sensitive and two (8%) were fully 
resistant to Eth. Of the 73 isoniazid resistant strains, 
65 (89.1%) were sensitive, six (8.2%) fully resistant 
and two (2.7%) strains showed intermediate resistance 
to Eth. Of the 11 ethambutol resistant strains, 10 
(90.9%) were sensitive to and 1 (9.1%) fully resistant 
to Eth. Of the 24 streptomycin resistant strains, 22 
(91.7%) were sensitive and two (8.3%) were fully 
resistant to Eth (Table 5). 
Table 5: Susceptibility profile of the 25 MDR–TB 











Eth 23 (92) 2 (8) 25 (100) 
 
Out of the 25 MDR-TB strains tested, two (8%) were 
fully resistant to Eth and 23 (92%) were sensitive to it 
(Table 6). 
 
















Rifampicin (25) 23 (92) 2 (8) 2 (8) 0 (0) 0.337 
Isoniazid (73) 65 (89.1) 8 (11) 6 (8.2) 2 (2.7) 0.083 
Ethambutol (11) 10 (90.9) 1 (9.1) 1 (9.1) 0 (0) 0.838 
Streptomycin (24) 22 (91.7) 2 (8.3) 2 (8.3) 0 (0) 0.325 
 
Discussion 
The findings of this study indicate that second-line 
drug resistant TB has not only developed but is also  
 
high in Eth. It was also established that MTB has 
developed further resistance to anti-TB drugs over the 
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years since drug resistant TB was first reported in 
Kenya. Furthermore MDR-TB was first isolated and 
documented in Kenya in the year 200216.  
Resistance to second-line drugs is associated with 
worse treatment outcomes than MDR-TB since an 
inadequate or poorly administered treatment regimen 
allows a drug-resistant strain to become the dominant 
strain in a patient infected with TB. Short-course 
chemotherapy for patients infected with drug-resistant 
strains may create even more resistance to the drugs in 
use. On-going transmission of established drug-
resistant strains in a population is also a significant 
source of new drug-resistant cases17. Based on this 
study, Eth is the drug with the highest resistance at 
41.2% compared to the other SLDs tested. This high 
Eth resistance may hamper treatment of MDR-TB 
patients in Kenya since Eth is one of the key drugs 
used in the regimen of treatment of MDR-TB. 
In a study done by Heym et al, 16 out of 36 isoniazid 
resistant strains were found to be also resistant to 
Eth18. In this study 8 strains found to be resistant to 
both Eth and isoniazid. This is the first time in Kenya 
that isoniazid and Eth resistance association has been 
documented. Eth, like isoniazid is considered an 
inhibitor of mycolic acid synthesis but much less 
active against MTB3. Studies have shown that for 
certain strains, a low level of isoniazid resistance is 
correlated with co-acquisition of Eth resistance, 
suggesting that both share a common molecular target 
most likely involving the mab-inhA genes that are 
involved in resistance9. 
Relationship between isoniazid and Eth could be 
because resistance genes encode information on a 
variety of mechanisms that microorganisms use to 
withstand the inhibitory effects of specific 
antimicrobials. These mechanisms can confer 
resistance to other antimicrobials of the same class 
and sometimes to several different antimicrobial 
classes19. In this study, isoniazid resistant strains 
showed high resistance to Eth indicating that the two 
drugs may be correlated in resistance. It is known that 
high level resistance to isoniazid is associated with 
mutations to catalase peroxidase gene, katG20, and 
that cross-resistance to isoniazid and ethionamide 
results from mutations in the inhA gene9. 
 
Conclusions 
The level of resistance to Eth was high, and continued 
failure to improve TB control will impact negatively 
on the outcome of management of MDR-TB 
especially in Kenya where the use of this drug is 
almost mandatory. Close monitoring of Eth before 
embarking on individual patient management is 
necessary. With the presence of second-line anti-TB 
drug resistance strains in Kenya, control of TB will 
rely on quality assured and nationally recommended 
treatment regimen administered under strict 
supervision as part of the Directly Observed Therapy 
Short Course Plus (DOTS-Plus) programme.  
 
Recommendations 
Since this study showed a trend towards the co-
relationship between isoniazid and Eth resistance, 
further studies should be carried out to show this 
relationship. All isoniazid resistant strains should also 
be tested for Eth resistance. Close monitoring of Eth 
resistance before initiating individual patient 
management may be necessary. 
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